Miriplatin

CAS: 141977-79-9

Ref. 3D-RFA97779

Produktinformation

• Name: Miriplatin
• Synonyme: (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-κN¹,κN²]bis(tetradecanoato-κO)platinum, Cyclohexane-(1R,2R)-diamineplatinum(II) dimyristate, DACHPt(II)(Myr)2, Dachpm, Miripla, Platinum, (1,2-cyclohexanediamine-N,N′)bis(tetradecanoato-O)-, [SP-4-2-(1R-trans)]-, Platinum, (1,2-cyclohexanediamine-κN,κN′)bis(tetradecanoato-κO)-, [SP-4-2-[1R-(trans)]]-, Platinum, [(1R,2R)-1,2-cyclohexanediamine-κN,κN′]bis(tetradecanoato-κO)-, (SP-4-2)-, Platinum, [(1R,2R)-1,2-cyclohexanediamine-κN¹,κN²]bis(tetradecanoato-κO)-, (SP-4-2)-, Sm-11355, Smp-11355, [(1R,2R)-1,2-Cyclohexanediamine]bis(myristato)platinum, Platinum, [(1R,2R)-1,2-cyclohexanediamine-κN1,κN2]bis(tetradecanoato-κO)-, (SP-4-2)-, (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2]bis(tetradecanoato-κO)platinum

Beschreibung

Miriplatin is a platinum-based anticancer drug that binds to DNA in a cell and inhibits the growth of cancer cells. This drug is used in combination with other chemotherapeutic agents, such as epirubicin and hyperproliferative diseases. Miriplatin can be detected by fluorescence probe and plasma mass spectrometry. A new analytical method for miriplatin was developed using multivariate logistic regression to predict the risk of hepatic impairment during treatment with miriplatin. It has been shown that miriplatin can be used as an alternative treatment for infectious diseases caused by Gram-positive bacteria, such as Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis. It is also known that the disulfide bond in miriplatin is susceptible to reduction by sodium carbonate under acidic conditions, which may lead to a decrease in its cytotoxic activity.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 764 g/mol
• Formel: C₂₈H₅₄O₄Pt·C₆H₁₄N₂
• Reinheit: Min. 95%